Harrow, Inc. (HROW) Aandelenanalyse

Bedrijfsoverzicht

Harrow, Inc. is an eyecare pharmaceutical company dedicated to the discovery, development, and commercialization of ophthalmic pharmaceutical products within the United States market. The firm operates specifically within the Healthcare sector, functioning in the specialized industry of Drug Manufacturers - Specialty & Generic, which implies a focus on niche therapeutic areas requiring rigorous regulatory compliance and distinct manufacturing capabilities. At the current scale, the company carries a market capitalization of $1.34 billion and generates annual revenue of $272.30 million while employing a workforce of 373 individuals. These valuation and revenue figures indicate that Harrow, Inc. has established itself as a mid-to-large cap entity with significant operational capacity, suggesting a substantial footprint in the ophthalmic drug landscape relative to smaller generic manufacturers. The combination of a robust market cap and diversified operational segments, including both Branded and ImprimisRx, points to a business model capable of sustaining independent operations while navigating the competitive dynamics of specialty pharmaceutical distribution.

Financiële gezondheid

The company reported revenue of $272.30 million over the trailing twelve months, yet recorded a net income of -$5,139,000, while maintaining an EBITDA of $48.82 million. The significant gap between the positive EBITDA of $48.82 million and the negative net income reveals a substantial cost structure impact from interest expenses and non-operating charges that erode bottom-line profitability despite strong core earnings power. Harrow, Inc. demonstrates exceptional financial flexibility with free cash flow of $45.18 million, a metric that indicates the company can fund ongoing operations and strategic initiatives without relying on external capital markets. The gross margin stands at 75.1%, reflecting high pricing power or low cost of goods sold typical in specialty compounding, while the operating margin of 17.5% shows efficient management of overhead expenses before interest and taxes. However, the profit margin of -1.9% underscores the burden of financial obligations on the final earnings per share. On the balance sheet, total cash holdings of $75.06 million are outweighed by total debt of $251.98 million, resulting in a debt-to-equity ratio of 483.72, which characterizes a highly leveraged financial position. Despite the leverage, the current ratio of 2.20 indicates robust short-term liquidity, suggesting the firm possesses sufficient current assets to cover its current liabilities with a comfortable safety margin. Return on Equity is reported at -8.5%, signaling that shareholder equity is currently being depleted, whereas Return on Assets sits at 4.8%, indicating that the company is still generating positive operating returns on its asset base before financing costs.

Waarderingsbeoordeling

Valuation metrics for Harrow, Inc. present a forward P/E of 13.21, whereas the trailing twelve-month P/E ratio is listed as N/A due to the lack of net income. The absence of a trailing P/E and the presence of a forward P/E imply that the market is pricing in a significant turnaround in earnings, expecting future profitability to replace current losses. The price-to-book ratio is elevated at 25.50, indicating that the market values the company at a substantial premium over its net tangible assets, likely driven by the intangible value of its proprietary drug portfolio and pipeline. Alternative valuation metrics such as the price-to-sales ratio of 4.91 and an EV/EBITDA of 31.02 suggest that investors are paying a high multiple for revenue growth and operational cash generation rather than current earnings power. Regarding price momentum, the stock trades between a 52-week high of $54.85 and a 52-week low of $21.12, meaning the current share price is trading significantly below the recent peak but well above the bottom of the trading range. The beta value of 0.31 indicates that the stock exhibits low price volatility relative to the broader market, moving less than half as much as the S&P 500 in response to general market fluctuations.

Growth & Income

Harrow, Inc. has achieved revenue growth of 33.3% year-over-year, which contrasts sharply with earnings growth of -10.3%, indicating that top-line expansion is occurring faster than bottom-line recovery. The divergence between revenue growth and negative earnings growth implies that recent revenue increases are being offset by rising costs, interest expenses, or one-time charges that prevent a proportional increase in net income. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, meaning it reinvests all available earnings and cash flow back into the business rather than distributing income to shareholders. This strategy aligns with the company's need to fund research and development or pay down debt to address its high leverage levels. The overall growth and income profile reflects a classic growth-at-a-reasonable-price scenario where capital appreciation is driven by revenue expansion and operational efficiency improvements rather than current yield or immediate profitability.